Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gleevec Sales Gains May Come From Increased Dosing Compliance

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis is hoping to boost sales of its oncologic Gleevec (imatinib) by increasing patient compliance with the daily dosing regimen

You may also be interested in...

Diovan Positioned For Growth Following Sales Force Shift, Novartis Says

Despite disruption in first quarter, the company says a realignment of reps will help the hypertension drug by better targeting high-volume prescribing "tier one" doctors. Sales of the angiotensin II receptor blocker also will be aided by new dosage strengths, indications and price increases, Novartis says.

Gleevec Could Get Higher Maximum Approved Dose

Novartis is seeking to increase the maximum approved dose of its oncologic Gleevec (imatinib mesylate) to 800 mg, Oncology President David Epstein said Jan. 20

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts